Equity

Is Medtronic plc (MDT) undervalued?

$93.23+2.50% todayNYSE · USD · last traded 2026-09-14 16:45 UTC

Medtronic plc trades on a P/E of 25.00 against earnings growth of 9.8% a year over the last 3 years, giving a PEG ratio of 2.56 — above the 2.0 level conventionally read as expensive relative to growth.

Earnings figures are measured from MDT’s filed annual accounts, not estimated. PEG compares price to earnings growth alone — it says nothing about debt, cash generation, or what an acquirer would pay. Read it alongside the figures below rather than on its own.

PEG ratio2.56
01.02.03.0+
Convention reads below 1.0 as inexpensive relative to growth and above 2.0 as expensive, though typical ranges differ sharply by sector.
P/E ratio25.00
earnings growth (3-year CAGR)9.8%
PEG ratio2.56
Measured from MDT's filed annual accounts. Trailing, not forecast.
01

What it would cost to buy MDT

Enterprise value is what it would cost to take the whole company: every share at today’s price, plus the debt an acquirer assumes, less the cash they receive. For Medtronic plc that is $145.72B.

Every term below is a line item from a filed statement. The numbers beside each one open the filing it came from — balance-sheet figures arrive already scaled, so there is no “in thousands” to catch you out.

1.28B shares · 10-Q cover page

market capitalisation$119.26B
total debt$28.15B
cash & equivalents$1.69B
enterprise value$145.72B
Balance-sheet terms as reported to 2026-07-31.
Enterprise-value multiples for Medtronic plc
MeasureValue
Diluted earnings per shareto 2026-04-24$3.73
P/E ratioto 2026-04-2425.0
Earnings growth (3-year CAGR)to 2026-04-249.8%
PEG ratioto 2026-04-242.6
Market capitalisationto 2026-08-28$119.26B
Total debtto 2026-07-31$28.15B
Net debtto 2026-07-31$19.33B
Enterprise valueto 2026-07-31$145.72B
EBITDAto 2026-04-24$9.43B
Free cash flowto 2026-04-24$5.43B
EV / EBITDAto 2026-04-2415.5×
EV / Salesto 2026-04-244.0×
Free cash flow yieldto 2026-04-244.5%
Net debt / EBITDAto 2026-04-242.1×
Return on capital employedto 2026-04-248.3%

Earnings growth is measured across Medtronic plc’s own filed annual accounts. PEG conventionally uses forecast growth from analyst estimates; filings contain only history, so this is trailing growth and will read differently from a PEG quoted elsewhere.

02

Against the sector

MDT against 38 listed companies sharing its classification — Surgical & Medical Instruments & Apparatus and related industries. A multiple means little on its own; the column that matters is the gap.

MDT compared with the median of 38 sector peers
MeasureMDTSector medianDifference
EV / EBITDA*15.5×19.4×3.9×
EV / Sales*4.0×5.3×1.2×
Net debt / EBITDA2.1×1.6×+0.5×
Return on capital employed8.3%12.1%3.9%
Operating margin17.8%18.6%0.8%
Free cash flow margin14.9%16.5%1.6%
Compared against

A, ALGN, AME, BAX, BDX, BSX, COHR, COO, DHR, DXCM, EW, FTV, GEHC, GRMN, ISRG, KEYS, KLAC, LHX, MMM, MTD, NOC, PODD, RMD, ROK, ROP, RVTY, SOLV, STE, SYK, TDY, TER, TMO, TRMB, TT, VLTO, WAT, WST, ZBH.

Medians are taken across peers where the measure could be computed, so the sample differs by row. Green marks the direction conventionally read as cheaper or stronger — it is a direction, not a recommendation. * Price-based multiples move with the market; peer figures are a snapshot taken 2026-09-09. The remaining rows come from filed statements and hold until the next reporting season.

03

Market ratios

Price-based ratios from market data. Anything drawn from a filed statement is in the enterprise-value section above, with its source.

Valuation and financial-health metrics for Medtronic plc (MDT)
MetricValue
Price$93.23
PEGY ratio
Dividend yield3.09%
Price / book
Price / sales
Return on equity10.7%
Profit margin
Operating margin
Debt / equity56.05
Current ratio
Beta0.56
52-week range$73.31 – $106.33

Not reported for MDT: pegy ratio, price / book, price / sales, profit margin, operating margin, current ratio. A dash means the figure was not available from the source, not that it is zero.

04

Compare and chart

Compare MDT vs Competitors

Use the calculator below to see how MDT stacks up against other stocks in the same industry.

Enter a ticker to pull its filings and build the valuation from the statements.

Enter a ticker to begin

Quick picks:

05

About MDT’s valuation

What is the PEG ratio for Medtronic plc (MDT)?
Medtronic plc has a PEG ratio of 2.56, from a P/E of 25.00 and earnings growth of 9.8% a year measured across 3 years of filed accounts. That is above the 2.0 level conventionally read as expensive relative to growth. Note that PEG is conventionally quoted against forecast growth; this uses reported history, so it will differ from a PEG you see elsewhere.
Is MDT undervalued right now?
That depends on the measure. On PEG, MDT reads 2.56, above the 2.0 level conventionally read as expensive relative to growth. The PEG ratio compares price to earnings growth alone — it ignores debt, cash generation and asset backing, so it is a starting point rather than a conclusion. The enterprise-value measures above account for debt and cash; they often tell a different story.
What is the PEGY ratio for MDT?
The PEGY ratio for Medtronic plc is —. PEGY adds the dividend yield of 3.09% to the growth rate in the denominator, which gives a fairer reading of companies returning cash as income rather than growth.
Where do these MDT figures come from?
Market price and capitalisation come from live market data; earnings, growth and dividend figures come from Medtronic plc's published financial statements. Every derived ratio on this page shows the arithmetic that produced it.

This page describes published financial data. It is not investment advice and makes no recommendation to buy or sell MDT.